Sino Biopharmaceutical (SBMFF) Projected to Post Quarterly Earnings on Thursday

Key Points

• Sino Biopharmaceutical is expected to issue quarterly results before the market opens on Thursday, March 26, with analysts forecasting earnings of $0.0086 per share and revenue of $2.0675 billion.
• Shares opened at $0.83 and have a 52‑week low/high of $0.44 / $1.24; the company shows a debt‑to‑equity of 0.07, quick ratio of 1.28, current ratio of 1.36, and 50‑/200‑day SMAs of $0.85/$0.91.
• Sino Biopharmaceutical is a Hong Kong‑incorporated pharma investment holding company focused on R&D, manufacturing and commercialization across three core segments: infusion solutions, small‑molecule synthetic pharmaceuticals and innovative biologics.

Sino Biopharmaceutical (OTCMKTS:SBMFF - Get Free Report) is anticipated to issue its results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of $0.0086 per share and revenue of $2.0675 billion for the quarter.

Sino Biopharmaceutical Stock Performance

OTCMKTS SBMFF opened at $0.83 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.28 and a current ratio of 1.36. Sino Biopharmaceutical has a 52-week low of $0.44 and a 52-week high of $1.24. The company has a 50-day simple moving average of $0.85 and a 200 day simple moving average of $0.91.

Sino Biopharmaceutical Company Profile

Sino Biopharmaceutical Limited OTCMKTS: SBMFF is a Hong Kong–incorporated investment holding company principally engaged in the pharmaceutical sector. Founded in 2000 and listed on the Hong Kong Stock Exchange in 2006, the company has developed an integrated business model that spans research and development, manufacturing and commercialization of healthcare products. Through its subsidiaries, Sino Biopharmaceutical focuses on enhancing China's domestic pharmaceutical infrastructure while expanding its footprint across key therapeutic areas.

The company's product portfolio is organized into three core segments: infusion solutions, small-molecule synthetic pharmaceuticals and innovative biologics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.